WO2021105372A1 - Verfahren zum erstellen eines befundes zur funktionalität eines anorexigenen signalwegs für einen patienten - Google Patents
Verfahren zum erstellen eines befundes zur funktionalität eines anorexigenen signalwegs für einen patienten Download PDFInfo
- Publication number
- WO2021105372A1 WO2021105372A1 PCT/EP2020/083643 EP2020083643W WO2021105372A1 WO 2021105372 A1 WO2021105372 A1 WO 2021105372A1 EP 2020083643 W EP2020083643 W EP 2020083643W WO 2021105372 A1 WO2021105372 A1 WO 2021105372A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fas
- indicator
- sample matrix
- measured values
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 230000002891 anorexigenic effect Effects 0.000 title claims abstract description 22
- 239000011159 matrix material Substances 0.000 claims abstract description 54
- 238000004590 computer program Methods 0.000 claims abstract description 23
- 238000001228 spectrum Methods 0.000 claims abstract description 17
- 238000004458 analytical method Methods 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 3
- 208000008589 Obesity Diseases 0.000 claims description 26
- 235000020824 obesity Nutrition 0.000 claims description 25
- 239000012491 analyte Substances 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 206010061428 decreased appetite Diseases 0.000 claims description 8
- 238000007405 data analysis Methods 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 description 10
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 9
- 101710200814 Melanotropin alpha Proteins 0.000 description 9
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 9
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 8
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 8
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000000813 peptide hormone Substances 0.000 description 7
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 7
- 206010033307 Overweight Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000578 anorexic effect Effects 0.000 description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007257 malfunction Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000036391 Genetic obesity Diseases 0.000 description 2
- 102000004378 Melanocortin Receptors Human genes 0.000 description 2
- 108090000950 Melanocortin Receptors Proteins 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 208000037493 inherited obesity Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- ZYDMZKPAPSZILB-WKNDHWIVSA-N 53917-42-3 Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C(C)C)C1=CC=CC=C1 ZYDMZKPAPSZILB-WKNDHWIVSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 101150093308 POMC gene Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- FRIPRWYKBIOZJU-UHFFFAOYSA-N fluorone Chemical compound C1=CC=C2OC3=CC(=O)C=CC3=CC2=C1 FRIPRWYKBIOZJU-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Definitions
- the present invention relates to a method for creating a finding on the functionality of an anorexigenic signal path for a patient or test person.
- the invention also relates to a computer program product for carrying out such a method and to a storage means with a computer program product of the generic type stored thereon.
- the invention also relates to an analysis device for creating such a finding.
- obesity In addition to excessive energy consumption in the context of unhealthy diets, obesity can also be genetically determined or at least influenced. According to the international classification of diseases and related health problems, obesity is classified as an endocrine, nutritional and metabolic disease.
- Body mass index is a rough measure of obesity.
- the BMI is calculated by dividing the body weight in kilograms by the body height in meters squared. If the BMI is over 30 kg / m 2 , it is referred to as obesity according to the World Health Organization.
- the BMI also enables the classification into different degrees of obesity. With a BMI between 30 and 34.9, one speaks of obesity grade I, with a BMI between 35 and 39.9 of obesity grade II and with a BMI of 40 and more of obesity grade III or Obesity permagna or morbid obesity.
- the BMI is only a rough guide.
- a BMI report is not sufficient for targeted treatment of affected patients. In particular, based on the BMI, no distinction can be made between overweight due to a disturbed energy balance and a possible genetic obesity. Other approaches known in the prior art for the diagnosis and subsequent treatment of obesity have not yet brought the desired results.
- the object of the present invention is to at least partially take into account the above-described problems.
- a method for making a FAS finding for the functionality of an anorexigenic signal path for a patient is provided.
- the procedure consists of the following steps:
- Determining at least one first FAS indicator from the sample matrix Determining at least one second FAS indicator from the sample matrix, wherein the at least one second FAS indicator differs from the at least one first FAS indicator, and
- FAS is to be understood as an abbreviation for the functionality of an anorexigenic signaling pathway.
- the FAS finding is to be understood as a finding on the functionality of an anorexic signaling pathway.
- An FAS indicator is accordingly to be understood as an indicator for assessing or diagnosing the functionality of an anorexigenic signal path.
- the FAS diagnosis can be created.
- the patient can achieve the desired feeling of satiety at different times, which helps him with a regulated diet.
- the findings on the functionality of the anorexigenic signal path reliably allow direct conclusions to be drawn about obesity, in particular genetic obesity. It was also recognized that the function of the signal path can be assessed using various indicators. This knowledge was further developed in such a way that the FAS findings are created using a spectrum of indicators with the various FAS indicators. From the joint consideration of several different ADAS indicators, a significant gain in information or a correspondingly high accuracy of the ADAS findings can be achieved. The spectrum of indicators is therefore to be understood as a collection of different FAS indicators. According to the invention, several different FAS indicators are considered collectively.
- the at least one first FAS indicator differs in particular in its type from the at least one second FAS indicator. This means that the at least one first FAS indicator does not only differ in amount and / or scope from the at least one second FAS indicator.
- the fact that the indicator spectrum has the at least one first FAS indicator and the at least one second FAS indicator is to be understood as meaning that the respective FAS indicator can in principle have an unlimited number of different FAS indicators.
- the indicator spectrum can also have three or more ADAS indicators that differ from one another.
- FAS finding can be understood to mean a finding under which the present medically relevant, physical or psychological phenomena, circumstances, changes and / or states of the patient are ascertained regarding the functionality of his anorexigenic signal path.
- Under deploying the sample matrix is to be understood as providing at least one sample matrix.
- the patient can also be understood as a test subject.
- the at least one first FAS indicator to have an MSH concentration, in particular an ⁇ -MSH concentration, in the sample matrix.
- MSH concentration in particular an ⁇ -MSH concentration
- POMC proprotein proopiomelanocortin
- the hypothalamic a-MSH plays a central role in weight regulation, as signals from the periphery, the fat content of the body and the filling of the stomach, lead to the release of a-MSH, which mediates the feeling of satiety via the central melanocortin receptors.
- Mutations in the POMC gene can cause a deficiency in the proprotein and thus in the ⁇ -MSH. Due to the interrupted signal chain, no saturation signal can be generated. This can lead to uncontrolled, greatly increased food intake and thus to extreme obesity. In experiments within the scope of the present invention, it was possible to show that saturation is associated with an increase in the ⁇ -MSH concentration, in particular in the liquor or cerebrospinal fluid. Defects in this central ⁇ -MSH signal transmission have so far only been diagnosed on the basis of the underlying genetic defects.
- the at least one first FAS indicator can have a CLIP concentration in the sample matrix.
- a CLIP concentration is to be understood as the concentration of corticotropin-like intermediate peptide (CLIP).
- CLIP corticotropin-like intermediate peptide
- the at least one second FAS indicator can have the concentration of at least one peptide hormone in the sample matrix.
- concentrations or the ratios of relevant peptide hormones or at least one peptide hormone diagnostic statements can be made on the FAS finding.
- the ⁇ -MSH concentration to be determined in the blood can be determined indirectly by measuring relevant peptide hormones.
- the concentration of the at least one peptide hormone is preferably determined by a multiplex method.
- the at least one second FAS indicator in each case has the concentration of different peptide hormones in the sample matrix. This enables a high level of accuracy of the FAS findings to be achieved.
- At least one third FAS indicator which is determined in advance in the context of a big data analysis, is determined for creating the FAS findings, which is different from the first FAS indicator and the second FAS indicator differentiates, the at least one third FAS indicator in particular having at least one of the following features: BMI of the patient is greater than 35,
- Obesity syndrome type ll-lll of the patient clinical symptoms of obesity of the patient,
- the FAS finding can be specified more precisely by means of a big data analysis using suitable further FAS indicators to a degree that is not possible when using conventional methods for creating a generic finding sentence white was imaginable.
- the accuracy of the medical and professional assessment or diagnosis can be based on the larger amounts of data measured in laboratory values, both in patients with known diagnoses and in healthy individuals and patients with an unknown diagnosis with statistical and mathematical evaluation using a machine learning process and / or Big data analysis according to the invention can be raised to a new level.
- the underlying experience can lead to an overall assessment of all measured values or ADAS indicators, which then not only takes into account known questions, but also reveals previously unknown facts, without pre-existing clinical suspicions or corresponding questions can be.
- the at least one first FAS indicator is determined on the basis of at least one measured value for a first analyte in the sample matrix and / or the at least one second FAS indicator is determined on the basis of at least one measured value for a second analyte is determined in the sample matrix, wherein the first analyte and the second analyte are in particular at different points within a control loop or a synthesis chain.
- the advantage of this approach is that the functionality of the control loop or the corresponding signal cascade can be measured and verified at various points.
- the individual analytes are dependent on one another. That is, if one analyte is high or low, the other must also be correspondingly high or low.
- the analytes which can be taken from both liquid and dried sample matrices, can be extracted from the sample matrix using immunoprecipitation (IP) or solid phase extraction (SPE).
- IP immunoprecipitation
- SPE solid phase extraction
- the analytes can be bound to the column material and isolated under reversed-phase conditions by selecting a suitable antibody in each case or according to physicochemical properties using a C18 material. Alternatively, other materials such as mixed-mode materials are also conceivable and can be used accordingly.
- a clean extract can be obtained by washing the analytes with aqueous solvents and subsequent elution with organic solvents. The extracted analytes can then be concentrated by evaporating the organic solvent and reconstituted in an aqueous solution.
- the extracted analytes can be separated from other matrix components of the sample using reversed phase chromatography in an online LC-MS / MS method.
- the extracted analytes can also be chemically modified, in particular derivatized. Methods such as Immunoaffinity Chromatography (IAC) and Hydrophilic Interaction Liquid Chromatography (HILIC) are also possible.
- IAC Immunoaffinity Chromatography
- HILIC Hydrophilic Interaction Liquid Chromatography
- a mass spectrometric analysis can be carried out in a multi-analyte method in MRM mode (multiple reaction monitoring), in which specific mass transitions of doubly or triply charged analyte ions can be fragmented in the collision cell of the mass spectrometer and the fragment ions can be detected.
- the quantitative determination of the analytes can be carried out by means of external calibration by doping internal standards with stable isotopes.
- first measured values are also possible for several first measured values to be determined for a first analyte in the sample matrix and / or for several second measured values to be determined for a second analyte in the sample matrix, the first measured values being expanded to form a first set of measured values and / or the second measured values are expanded to form a second group of measured values, the at least one first FAS indicator being determined using the first group of measured values and the at least one second FAS indicator being determined using the second group of measured values.
- dynamic weighting of the ADAS indicators is possible, for example in the case of widely differing ADAS indicators Indicators possible.
- a particularly meaningful FAS finding can be created on the basis of the quantitative deviation value that can be determined in this way.
- the first measured values to be expanded to a first set of measured values by a statistical measure and / or for the second measured values to be expanded to a second set of measured values by a statistical measure.
- the respective first and second measured values are preferably expanded by a mathematical and / or statistical method.
- a desired value or indicator in the form of the associated family of measured values can be mathematically formed and interpreted on the basis of the respective first and second measured values.
- the informative value of the calculated indicators can be determined by statistical evaluation of a large number of measured values as part of a big data analysis in comparison with people with a known diagnosis.
- a quantitative, mean first deviation value of the first set of measured values from a predefined first reference value and / or a quantitative, mean second deviation value of the second set of measured values from a predefined second reference value are determined and the FAS - Findings are made depending on the first deviation value and / or the second deviation value. With the help of this procedure, a relatively precise FAS finding can be made.
- the at least one first FAS indicator, the at least one second FAS indicator and / or the at least one third FAS indicator are multiplied by a weighting factor and the FAS indicator Findings are created depending on the weighted FAS indicators.
- a blood sample, a whole blood sample, a plasma sample, a serum sample, a liquor sample and / or a urine sample, each in liquid or dry form is preferably used as the sample matrix.
- the analytes are, as explained above, extracted from the dried sample matrix with suitable extraction agents, it being possible to carry out rehydration with or without an organic solvent content. If dry blood is used, enzymatic cleavage of the analytes into peptide fragments can be extended.
- a human plasma sample is preferably used as the sample matrix.
- a human blood sample particularly preferably a human dry blood sample, can also be used.
- a computer program product which is configured and designed to carry out a method as described in detail above on a sample matrix provided.
- a computer program product according to the invention thus brings the same advantages as have been described in detail with reference to the method according to the invention.
- the computer program product can be implemented as a computer-readable instruction code in any suitable programming language such as, for example, in JAVA or C ++.
- the computer program product can be stored on a computer-readable storage medium such as a data disc, a removable drive, a volatile or non-volatile memory, or a built-in memory / processor.
- the instruction code can program a computer or other programmable device such as a controller to perform the desired functions.
- the computer program product can be provided in a network such as the Internet, for example, from which it can be downloaded by a user if necessary.
- the computer program product can be implemented both by means of a computer program, ie software, and by means of one or more special electronic circuits, ie in hardware, or in any hybrid form, ie by means of software components and hardware components a storage means is provided with a computer program product according to the invention stored thereon.
- Another aspect of the present invention relates to an analysis device for creating a FAS finding for a patient with a computer program product installed therein, as described above, having a determination device for determining at least one first FAS indicator from a sample matrix and for determining at least a second FAS indicator from the sample matrix, wherein the at least one second FAS indicator differs from the at least one first FAS indicator, and a creation device for creating the FAS findings based on an indicator spectrum, which includes the at least one first FAS indicator and the has at least one second FAS indicator.
- An analysis device according to the invention thus also has the advantages detailed above.
- FIG. 1 shows an illustration to explain a method according to a first embodiment variant of the present invention
- FIG. 2 shows an illustration to explain a method according to a second embodiment variant of the present invention
- FIG. 3 shows an illustration to explain a method according to a third embodiment variant of the present invention
- FIG. 4 shows an illustration to explain a method according to a fourth embodiment variant of the present invention
- FIG. 5 shows a representation to explain a method according to a fifth embodiment variant of the present invention
- FIG. 6 shows an illustration to explain a method according to a sixth embodiment variant of the present invention
- FIG. 7 shows an illustration for explaining a method according to a seventh embodiment variant of the present invention.
- FIG. 8 shows a block diagram to show an analysis device with a storage means and a computer program product stored thereon according to an embodiment of the present invention.
- FIG. 1 shows a test tube in which there is a sample matrix 10 in the form of a blood sample from the patient.
- a first FAS indicator 11, a second FAS indicator 12, and a third FAS indicator 13 are now determined from the sample matrix 10, the three FAS indicators 11, 12, 13 differing from one another.
- the first FAS indicator 11 has an ⁇ -MSFI concentration in the sample matrix 10 and the second FAS indicator 12 has a concentration of a peptide-fluorone in the sample matrix 10.
- the functionality of the anorexic signal value can be designated as normal.
- the third FAS indicator shows that the functionality of the anorexic signal value may be disturbed.
- the three FAS indicators 11, 12, 13 form an indicator gate spectrum 20.
- a FAS finding 30 can now be derived from the overall view according to the indicator spectrum 20 to the effect that there is presumably no or only a very weak malfunction of the anorexogenic signal value. In other words, the anorexigenic signal level appears to be functioning normally or essentially normally. As a result, it can again be concluded that the obesity in question is not or hardly genetically determined.
- the illustrated identification of the FAS indicators 11, 12, 13 and the FAS finding 30 with “+” and also allows exactly the opposite finding, depending on a previously defined interpretation of the signs.
- Fig. 2 an example according to a second embodiment is shown, in which all FAS indicators 11, 12, 13 are negative, i.e. indicate a malfunction of the anorexic signal value according to a given interpretation.
- a FAS finding 30 can now be derived, which reveals a genetic malfunction of the anorexogenic signal value.
- a method according to a third embodiment will then be explained with reference to FIG. 3.
- several first measured values 11 n are determined for a first analyte in the sample matrix 10 and several second measured values 12n are determined for a second analyte in the sample matrix 10, the first measured values 11 n being expanded to form a first set of measured values 11 n + and the second measured values 12n are expanded to form a second set of measured values 12n +.
- the first FAS indicator 11 is determined on the basis of the first set of measured values 11 n + and the second FAS indicator 12 is determined on the basis of the second set of measured values 12n +.
- the first analyte and the second analyte are located at different points within a control loop or a synthesis chain.
- the values of the first set of measured values 11n + are compared with a first reference value 40 and the values of the second set of measured values 12+ are compared with a second reference value. Based on the respective comparison is now closed on the respective FAS indicator 11, 12.
- the reference values 40, 50 shown in FIG. 3 are only by way of example above or essentially above the respective families of measured values 11 n +, 12n +.
- the reference values can alternatively or additionally also be lower, in particular also below the respective sets of measured values, the present result being nevertheless achieved.
- a FAS indicator would also lead to a meaningful result if a set of measured values were above or essentially above a corresponding reference value. Both a raised and a lowered FAS indicator can therefore lead to the present FAS finding 30.
- the amount of the distance between the set of measured values and the reference value is decisive. This applies to all corresponding figures or associated embodiments.
- the first FAS indicator 11 has an ⁇ -MSFI concentration in the sample matrix 10 and the second FAS indicator 12 has a concentration of a peptide fluorone in the sample matrix 10. Accordingly, the first analyte corresponds to a-MSFI and the second analyte corresponds to the peptide fluoromon.
- a positive first FAS indicator 11 can be assumed, since the extended first set of measured values 11 n + is in a limit range to the first reference value 40 and partially above it.
- a positive second FAS indicator 12 can also be assumed, since the expanded second set of measured values 12n + is also located in a border area to the second reference value 50 and in some cases above it.
- the FAS finding 30 is therefore also positive. In other words, in this case a normal or essentially normal functioning or functionality of the anorexigenic signal path can be assumed.
- the first measured value set 11 n + With reference to the first measured value set 11 n +, it can be determined that, although it is relatively close to the first reference value 40, it is not close enough. A correspondingly negative value is therefore determined for the first FAS indicator 11.
- the second set of measured values 12n + is relatively far away from the second reference value 50, which is why the second FAS indicator is also rated negatively. This also results in a negative overall result in the sense of a corresponding FAS finding 30.
- a third FAS indicator 13 determined beforehand as part of a big data analysis is used to create the FAS finding 30, which is different from the first FAS Indicator 11 and different from the second FAS indicator 12, the third FAS indicator 13 being the patient's BMI.
- the third FAS indicator 13 turns out negative, while the first and the second FAS indicator 11, 12 each turn out to be positive. Therefore the FAS finding 30 is also positive.
- the third FAS indicator 13 is negative, while the first FAS indicator 11 is positive and the second FAS indicator 12 is negative. Due to the predominantly negative FAS indicators, the FAS finding 30 is also negative.
- the third FAS indicator 13 is positive, while the first FAS indicator 11 is positive and the second FAS indicator 12 is negative. Due to the predominantly positive FAS indicators, the FAS finding 30 is also positive in this case.
- a negative third FAS indicator 13 can be understood to mean that the patient has an increased or too high BMI. Depending on the definition and interpretation, as already mentioned above, a negative third FAS indicator 13 can of course also mean exactly the opposite.
- an analysis device 100 for creating a FAS finding 30 for a patient with a computer program installed therein product 90 is Darge provides.
- the computer program product 90 is stored on a storage means 80 and configured and designed to carry out a method as explained in detail above on a sample matrix 10 provided.
- the analysis device also has a determination device for determining a first FAS indicator 11 from the sample matrix 10 and for determining a second FAS indicator 12 from the sample matrix 10, the second FAS indicator 12 differing from the first FAS indicator 11.
- the analysis device has a creation device for creating the FAS finding 30 on the basis of the indicator spectrum 20, which has the first FAS indicator 11 and the second FAS indicator 12.
- the blood sample can be provided as a liquid blood sample or as a dry blood sample.
- a whole blood sample, a plasma sample, a serum sample, a liquor sample and / or a urine sample, in each case in liquid or dry form, can also be used as the sample matrix 10.
- the first FAS indicator 11 can also have a CLIP concentration in the sample matrix 10.
- the second FAS indicator 12 or a plurality of second FAS indicators 12 can each have the concentration of various peptide hormones in the sample matrix 10.
- the first FAS indicator 11, the second FAS indicator 12 and / or the third FAS indicator 13 can be multiplied by a weighting factor, the FAS finding 30 being created as a function of the weighted FAS indicators 11, 12, 13 .
- the first FAS indicator 11 can also be understood as a second FAS indicator 12 or a third FAS indicator 13, and vice versa. Furthermore, a plurality of first, second and / or third FAS indicators 11, 12, 13 can be determined in each case.
- the third FAS indicator 13 can have characteristics such as anorexia of the patient, a syndrome with obesity type ll-lll of the patient, clinical symptoms for obesity of the patient, and / or a direct indication of a disruption of the functionality of the anorexigenic signaling path, FAS , from the genetics of the patient. List of reference symbols
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20816453.3A EP4065983A1 (de) | 2019-11-29 | 2020-11-27 | Verfahren zum erstellen eines befundes zur funktionalität eines anorexigenen signalwegs für einen patienten |
CA3159699A CA3159699A1 (en) | 2019-11-29 | 2020-11-27 | Method for making a finding for the functionality of an anorexigenic signal path for a patient |
CN202080080685.9A CN114746756A (zh) | 2019-11-29 | 2020-11-27 | 创建关于患者的厌食信号路径功能性的检验结果的方法 |
AU2020392513A AU2020392513A1 (en) | 2019-11-29 | 2020-11-27 | Method of providing a finding for the functionality of an anorexigenic signal path for a patient |
US17/780,588 US20230003745A1 (en) | 2019-11-29 | 2020-11-27 | Method for making a finding for the functionality of an anorexigenic signal path for a patient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019218598.3A DE102019218598A1 (de) | 2019-11-29 | 2019-11-29 | Verfahren zum Erstellen eines Befundes zur Funktionalität eines anorexigenen Signalwegs für einen Patienten |
DE102019218598.3 | 2019-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021105372A1 true WO2021105372A1 (de) | 2021-06-03 |
Family
ID=73646328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2020/083643 WO2021105372A1 (de) | 2019-11-29 | 2020-11-27 | Verfahren zum erstellen eines befundes zur funktionalität eines anorexigenen signalwegs für einen patienten |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230003745A1 (de) |
EP (1) | EP4065983A1 (de) |
CN (1) | CN114746756A (de) |
AU (1) | AU2020392513A1 (de) |
CA (1) | CA3159699A1 (de) |
DE (1) | DE102019218598A1 (de) |
WO (1) | WO2021105372A1 (de) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050250215A1 (en) * | 2002-06-11 | 2005-11-10 | Mountjoy Kathleen G | Measurement of melanocortin peptides and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105874335B (zh) * | 2014-01-08 | 2019-03-12 | 雀巢产品技术援助有限公司 | 心外膜脂肪组织的生物标志物 |
DE102015208083B3 (de) * | 2015-04-30 | 2016-10-27 | Lipozyt Marker UG (haftungsbeschränkt) | Verfahren zur Prognose und/oder Diagnose einer Krankheit auf Basis von einer Probe aus Fettgewebe und Kit für dieses Verfahren |
-
2019
- 2019-11-29 DE DE102019218598.3A patent/DE102019218598A1/de active Pending
-
2020
- 2020-11-27 EP EP20816453.3A patent/EP4065983A1/de active Pending
- 2020-11-27 AU AU2020392513A patent/AU2020392513A1/en active Pending
- 2020-11-27 WO PCT/EP2020/083643 patent/WO2021105372A1/de unknown
- 2020-11-27 US US17/780,588 patent/US20230003745A1/en active Pending
- 2020-11-27 CN CN202080080685.9A patent/CN114746756A/zh active Pending
- 2020-11-27 CA CA3159699A patent/CA3159699A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050250215A1 (en) * | 2002-06-11 | 2005-11-10 | Mountjoy Kathleen G | Measurement of melanocortin peptides and uses thereof |
Non-Patent Citations (8)
Title |
---|
BARANOVA ANCHA ET AL: "Soluble Molecules Released From Visceral Adipose Tissue May Contribute to the Development of Advanced Non-Alcoholic Fatty Liver Disease", vol. 140, no. 5, Suppl. 1, 30 April 2011 (2011-04-30), pages S701, XP009526994, ISSN: 0016-5085, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0016508511629144> DOI: 10.1016/S0016-5085(11)62914-4 * |
HOGGARD NIGEL ET AL: "Plasma concentrations of alpha-MSH, AgRP and leptin in lean and obese men and their relationship to differing states of energy balance perturbation", CLINICAL ENDOCRINOLOGY., vol. 61, no. 1, 1 July 2004 (2004-07-01), GB, pages 31 - 39, XP055779946, ISSN: 0300-0664, DOI: 10.1111/j.1365-2265.2004.02056.x * |
KATSUKI ET AL: "Plasma levels of agouti-related protein are increased in obese men", 20010501, vol. 86, no. 5, 1 May 2001 (2001-05-01), pages 1921 - 1924, XP002972057 * |
LINCOLN G A ET AL: "Photo-neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: Lessons from the HPD sheep model", vol. 119, no. 3, 31 May 1998 (1998-05-31), pages 283 - 294, XP009525852, ISSN: 0742-8413, Retrieved from the Internet <URL:https://api.elsevier.com/content/article/PII:S0742841398000176?httpAccept=text/plain> DOI: 10.1016/S0742-8413(98)00017-6 * |
LOFRANO-PRADO M C ET AL: "Eating disorders in adolescents: Correlations between symptoms and central control of eating behavior", EATING BEHAVIORS, PERGAMON, AMSTERDAM, NL, vol. 12, no. 1, 1 January 2011 (2011-01-01), pages 78 - 82, XP027568366, ISSN: 1471-0153, [retrieved on 20101001] * |
MORELLO GIOVANNA ET AL: "Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 113, no. 17, 11 April 2016 (2016-04-11), US, pages 4759 - 4764, XP055778282, ISSN: 0027-8424, Retrieved from the Internet <URL:https://www.pnas.org/content/pnas/113/17/4759.full.pdf> DOI: 10.1073/pnas.1521304113 * |
See also references of EP4065983A1 * |
VEHAPOGLU AYSEL ET AL: "Alpha-Melanocyte-Stimulating Hormone and Agouti-Related Protein: Do They Play a Role in Appetite Regulation in Childhood Obesity?", JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, vol. 8, no. 1, 1 March 2016 (2016-03-01), pages 40 - 47, XP055778247, ISSN: 1308-5727, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805047/pdf/JCRPE-8-40.pdf> DOI: 10.4274/jcrpe.2136 * |
Also Published As
Publication number | Publication date |
---|---|
CN114746756A (zh) | 2022-07-12 |
DE102019218598A1 (de) | 2021-06-02 |
EP4065983A1 (de) | 2022-10-05 |
CA3159699A1 (en) | 2021-06-03 |
AU2020392513A1 (en) | 2022-06-09 |
US20230003745A1 (en) | 2023-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60026287T2 (de) | Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 | |
DE102010038014B4 (de) | Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung | |
Wehling et al. | Longitudinal changes in odor identification performance and neuropsychological measures in aging individuals. | |
EP0581023A1 (de) | Verfahren zur Analyse eines Bestandteils einer medizinischen Probe | |
EP3752838B1 (de) | Methode zur bestimmung der totalen histamin-abbaukapazität in biologischen proben | |
DE112019003251T5 (de) | Verfahren und Kits zur Detektion von 11-Dehydro-Thromboxan B2 | |
WO2021105372A1 (de) | Verfahren zum erstellen eines befundes zur funktionalität eines anorexigenen signalwegs für einen patienten | |
DE102019218597B4 (de) | Verfahren zum Erstellen eines Befundes zur Funktionalität eines anorexigenen Signalwegs für einen Patienten | |
EP1660880A1 (de) | Vorrichtung und verfahren zur quantitativen auswertung der in einer körperflüssigkeitsprobe enthaltenen polypeptide sowie marker zur erkennung von pathologischen zuständen | |
Mielke et al. | The influence of visual rehabilitation on secondary depressive disorders due to age-related macular degeneration: a randomized controlled pilot study | |
DE10060989B4 (de) | Verfahren zur Diagnose der Laktose-Intoleranz und Diagnosekit zur Durchführung des Verfahrens | |
DE69125536T2 (de) | Quantitative analyse von chiroinositol als anzeiger eines diabetischen zustandes | |
WO2018166546A1 (de) | Verfahren zur chromatografischen quantitativen bestimmung der aminosäuren valin, methionin, allo-isoleucin, isoleucin, leucin, tyrosin und phenylalanin im blutplasma | |
DE102012209059A1 (de) | Verfahren und Vorrichtung zur Bestimmung einer zeitlichen Änderung eines Biomarkers in einem Untersuchungsgebiet | |
WO2020043771A1 (de) | Diagnosemethode für erkrankungen die mit einer verminderten knochendichte einhergehen | |
PARADIS et al. | Studies of various diagnostic methods for canine hypothyroidism | |
DE602005004420T2 (de) | Verfahren zur bestimmung der wirksamkeit, der spezifität und der giftigkeit der blutbildenden prostaglandin-d2-synthase | |
DE69630131T2 (de) | Verfahren zur bestimmung des aggregationsgrades des beta a4-peptids | |
DE60102245T2 (de) | Anhand der konduktivität normalisierte bestimmung von analyten in urin zur diagnose von krankheiten | |
DE102018214660A1 (de) | Diagnosemethode für Erkrankungen die mit einer verminderten Knochendichte einhergehen | |
DE69625236T2 (de) | Verfahren zur reihenuntersuchung auf prostatakrebs durch messung des apolipoprotein-d-spiegels in körperflüssigkeiten | |
DE202007016404U1 (de) | Hygienepapier mit Indikator | |
Sugahara et al. | Improving the Diagnosis, Treatment, and Prevention of Endocrine Diseases Through Accurate and Reliable Laboratory Measurements With CDC Clinical Standardization Programs | |
DE102017216292A1 (de) | Biomarker zur Bestimmung der körperlichen Belastung von Menschen und Tieren und Verfahren zur Bestimmung der körperlichen Belastung sowie ein Kit zur Durchführung des Verfahrens | |
DE202024101215U1 (de) | Urinauffangbecher |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20816453 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3159699 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020392513 Country of ref document: AU Date of ref document: 20201127 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020816453 Country of ref document: EP Effective date: 20220629 |